Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer. - Wikidata - awgldk - TriplyDB

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q38270195

about

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Liquid biopsy genotyping in lung cancer: ready for clinical utility?Method for semi-automated microscopy of filtration-enriched circulating tumor cells.Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.RETRACTED: Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer.

P2860

Q26781333-D26B66C4-D98C-4A76-9580-45B85E4ECBA7 Q26801357-F58E7BCB-3DB9-47E8-8D44-2523B5497DE7 Q28067582-45065EB4-17F2-44CD-83EF-E6DB375903EA Q28077340-812CB762-A626-422D-B896-0EFDD8B9C726 Q33567037-0A374905-2138-4757-846C-F5F65DFB2198 Q36078204-9B483F62-9965-4AC5-B6D4-A1A36D95DE2D Q37268985-EBC0FF4A-F682-4827-BDB8-D9C1FAB1092E Q38626147-8DC59DF6-5E72-4441-BE05-E715B4CD1FEB Q41605016-378995E4-8854-4F3E-A1FA-A29F60061258 Q48045810-F14F8A1B-4EAE-4BB0-8BA7-6751DCEBEF37 Q54977996-072D6606-0DF1-4EA8-A0E1-D7FF1E1FF611

P2860

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q38270195

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

@en

type

label

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

@en

prefLabel

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

@en

P1433

Q38270195-CB4D372B-CDDF-48B8-AD35-78DE9E208EC9

P1476

Q38270195-D4B61EAE-BF37-4166-B95E-F0009EB09A75

P2093

Q38270195-1C5298E5-9CE4-423D-A4BA-840FC9822ED5

Q38270195-3B863E97-F63C-4750-8844-6234B1673C1C

Q38270195-98AE933D-0911-4FCB-AEB4-59E9E134C503

Q38270195-F9737882-8A72-4D94-8BD3-5E28A5F4E897

P2860

Q38270195-1172DBDC-80E0-42B3-85D2-F655AC760DB5

Q38270195-172C58F7-F155-4DFB-BA41-6A1D2E33501C

Q38270195-30F00629-B9EC-4A59-8618-6E96154CA55B

Q38270195-5A127431-A3C5-48C8-A73A-D427978E4425

Q38270195-63E3AFE9-ABF2-46E7-B910-21956EE3E3BF

Q38270195-693C96FE-C0AC-4251-B68C-0D335458E565

Q38270195-699C87A9-912D-46C2-B173-4694CC49FCFD

Q38270195-761727B1-6780-441B-AB7A-7B97CDF6E110

Q38270195-80F49FBE-6685-44CE-B30A-296A45EF45D5

Q38270195-923480E4-51E6-4029-AD48-874B5CD0DA43

P304

Q38270195-4301675F-0482-4C49-99E7-3F5EDF54A863

P31

Q38270195-CEA6B31F-2FD0-4701-A8CB-DF97A13F34A8

P356

Q38270195-1C9675B7-E265-42AB-8323-633009DC8AE0

P478

Q38270195-747B3C51-D298-4D85-9E41-EE1FED0A5A83

P50

Q38270195-B09625F2-BFDB-42B3-8356-8711E2902951

P577

Q38270195-7D50C22A-4A49-42A9-A08A-0B86AC519DC4

P5875

Q38270195-4040DF8D-6C88-40E7-A00F-7A2E8B0EE3D1

P698

Q38270195-A43A8AF3-C176-44D4-818A-1109160AA629

P932

Q38270195-9E1FD143-3D0B-4EEC-9D5D-C57BBCD784C5

P356

FONC.2014.00281

P1433

Frontiers in Oncology

P1476

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

@en

P2093

Emma Pailler

http://www.w3.org/2001/XMLSchema#string

Françoise Farace

http://www.w3.org/2001/XMLSchema#string

Nathalie Auger

http://www.w3.org/2001/XMLSchema#string

Vincent Faugeroux

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

The evolving genomic classification of lung cancer.

P304

281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00281

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268786857

http://www.w3.org/2001/XMLSchema#string

P698

25414829

http://www.w3.org/2001/XMLSchema#string

P932

4220657

http://www.w3.org/2001/XMLSchema#string